



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
SEP 07 2001
TECHNOLOGY CENTER 1600/2900

In re Application of)

ANDREW J. DANNENBERG)

Patent Application No. 09/554,604)

Filed: May 31, 2000)

For: CYCLOOXYGENASE-2 INHIBITION)

Group Art Unit: 1617

Examiner: S. Wang

RESPONSE TO ONE-MONTH ACTION

Honorable Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This is in response to the one-month action of August 14, 2001.

Please proceed on the basis of the following:

ELECTION:

The undersigned provisionally elects Group I (Claims 1-6) with traverse.

Remarks

Restriction has been required to one of Group I (Claims 1-6), Group II (Claims 7-11) and Group III (Claims 12-16).

As indicated above, the undersigned provisionally elects Group I (Claims 1-6) with traverse. Traverse is on the basis that all three groups should have the same area of search. Therefore, the groups do not have independent classification and the "independent" requirement of 35 U.S.C. 121 is not met. Withdrawal of the restriction requirement and examination of all claims is requested.

It is noted that the diseases mentioned for Group II (page 17, lines 19-20 of the application as filed) are included in those recited for Group I (page 3, line 8 of the application as filed). Thus, if the claims of Group I are found to be allowable, the claims of Group II should also be allowable.

Respectfully submitted,

JONES, TULLAR & COOPER, P.C.

By: 

Eric S. Spector
Reg. No. 22,495

JONES, TULLAR & COOPER, P.C.
P.O. Box 2266 Eads Station
Arlington, Virginia 22202
703 415 1500

Case CRF D-2165

September 6, 2001